Targeted Immune Checkpoint Blockade and Antibody-Drug Conjugates Transforming Esophageal Cancer Care
Integrating novel biological immunotherapies and targeted agents into clinical treatment algorithms is elevating survival outcomes in advanced esophageal malignancies. Detailed analysis within the Esophageal Cancer Market report demonstrates how anti-PD-1/PD-L1 immune checkpoint inhibitors paired with chemotherapy improve overall survival in metastatic esophageal squamous cell carcinoma (ESCC)...
0 Комментарии
0 Поделились